Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06719141 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
A Phase 3 study of Developmental and Epileptic Encephalopathy, sponsored by Longboard Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT06719141 is a Phase 3 study of Developmental and Epileptic Encephalopathy that is actively recruiting participants, run by Longboard Pharmaceuticals. The registered enrollment target is 320 participants, above the 48-participant average among 3 other Developmental and Epileptic Encephalopathy trials with a reported enrollment target (567% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT06719141, a Phase 3 study of Developmental and Epileptic Encephalopathy, is actively recruiting participants, sponsored by Longboard Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LP352
Study Locations (20)
Florida
- NW FL Clinical Research Group, LLC - Gulf Breeze
- University of Miami - 1120 NW 14th St - Miami
- Nicklaus Children's Hospital - PIN - Miami
- Research Institute of Orlando LLC - Orlando
- University of South Florida - 2 Tampa General Circle - Tampa
- Pediatric Epilepsy and Neurology Specialists - Tampa
California
- Children's Hospital Los Angeles - PIN - Los Angeles
- David Geffen School of Medicine at UCLA - Los Angeles
- The Stanford Division of Child Neurology - Palo Alto
- UCSF Children's Hospital - San Francisco
Georgia
- Children's Healthcare of Atlanta - Center for Advanced Pediatrics - PIN - Atlanta
- Rare Disease Research, LLC - Atlanta - RDR - PIN - Atlanta
Arkansas
- Arkansas Children's Hospital - PIN - Little Rock
Colorado
- Children's Hospital Colorado. - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Idaho
- Consultants In Epilepsy and Neurology PLLC - Boise
Illinois
- Ann and Robert H Lurie Childrens Hospital of Chicago - PIN - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2024-11-11 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06719141
The ClinicalTrials.gov registry entry for NCT06719141 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 48-participant average among 3 other Developmental and Epileptic Encephalopathy trials with a reported enrollment target (567% higher). The listed sponsor is Longboard Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Developmental and Epileptic Encephalopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06719141 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT06719141 about?
NCT06719141 is a clinical study titled "A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)". This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance peri...
What is the current status of trial NCT06719141?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 2024-11-11. Estimated completion is 2026-11-30.
What conditions does trial NCT06719141 study?
This clinical trial studies the following conditions: Developmental and Epileptic Encephalopathy.
What interventions are being tested in trial NCT06719141?
The interventions under investigation include: Placebo (DRUG), LP352 (DRUG).
Who is sponsoring clinical trial NCT06719141?
This trial is sponsored by Longboard Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06719141 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Developmental and Epileptic Encephalopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy
ACTIVE NOT RECRUITING · Early Phase 1
-
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
COMPLETED · Phase 1
-
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.